Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2024-07-02 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
独立董事提名人声明与承诺（张金鑫）
Board/Management Information Classification · 95% confidence The document is a nomination statement and commitment declaration for an independent director candidate (张金鑫) by the board of 山西锦波生物医药股份有限公司. It details the qualifications, independence criteria, and legal compliance of the nominee. There are no financial statements, earnings data, or report attachments. The document is a formal announcement related to board/management changes, specifically the nomination of a new independent director. It is not an annual report, audit report, or any financial report. It is also not a proxy solicitation or voting result announcement. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 2627 characters, which is relatively short and consistent with a management announcement rather than a full report.
2024-07-02 Chinese
独立董事提名人声明与承诺（阎丽明）
Regulatory Filings Classification · 95% confidence The document is a formal statement nominating an independent director candidate for the company's board. It includes detailed declarations about the nominee's qualifications, independence, and compliance with relevant laws and regulations. There are no financial statements, earnings data, or report attachments. The document is a regulatory announcement related to board management but does not announce a change in board members or senior management itself. It is not a full report, earnings release, or proxy solicitation. Given the nature of the content—nomination and declaration related to board governance—it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-07-02 Chinese
2024年第一次职工代表大会决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's employee representative meeting, detailing the election of a new employee representative supervisor to the supervisory board. It includes meeting details, voting results, and compliance statements. There is no financial data, no mention of annual or interim reports, no audit information, no earnings data, and no regulatory filings or certifications. It is a formal announcement of a board/management related decision, specifically about the supervisory board composition. Therefore, it fits best under Board/Management Information (MANG). The document length is short but contains substantive content about management changes, not just an announcement of a report publication or a regulatory filing.
2024-07-02 Chinese
第三届董事会第三十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 30th meeting of the third board of directors of Shanxi Jinbo Biopharmaceutical Co., Ltd. It includes information about board member nominations, capital changes, loan applications, and plans for a shareholders meeting. The content focuses on board decisions and management changes, including nominations for the new board term. There is no financial statement or report data, nor is it a transcript or presentation. The document is not a report publication announcement but a formal board meeting resolution announcement. Therefore, it fits best under 'Board/Management Information' (MANG). The document length is 4398 characters, which is sufficient for a detailed board meeting resolution notice.
2024-07-02 Chinese
独立董事提名人声明与承诺（梁桐栋）
Board/Management Information Classification · 95% confidence The document is a nomination statement and commitment declaration for an independent director candidate (梁桐栋) for the board of 山西锦波生物医药股份有限公司. It details the qualifications, independence criteria, and legal compliance of the nominee. There is no financial data, no report or results announcement, no meeting materials, and no voting results. The document is a formal announcement related to board/management changes, specifically the nomination of a board member. Therefore, it fits the category of Board/Management Information (MANG). The document length is 2627 characters, which is consistent with a detailed announcement rather than a full report.
2024-07-02 Chinese
中信证券股份有限公司关于山西锦波生物医药股份有限公司关联交易事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from a sponsoring institution (中信证券股份有限公司) regarding a related party transaction involving a loan guarantee by the controlling shareholder of 山西锦波生物医药股份有限公司. It details the transaction overview, decision-making process, related party information, pricing policy, transaction content, purpose, impact, and the sponsor's verification opinion. The document is regulatory in nature, related to compliance and disclosure of a related party transaction, but it does not contain financial statements, earnings data, or detailed financial analysis. It is not an annual or interim report, earnings release, or audit report. It is also not a simple announcement of a report publication. Given the content and length (1487 characters), it fits best as a Regulatory Filing (RNS) because it is a compliance disclosure related to a related party transaction and sponsor verification, which does not fit other more specific categories.
2024-07-02 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.